Institutional members access full text with Ovid®

Retrospective Study on the Combination of Desferrioxamine and Deferasirox for Treatment of Iron-overloaded Thalassemic Patients: First Evidence of More Than 2 Years

Jetsrisuparb, Arunee MD; Komvilaisak, Patcharee MD; Wiangnon, Surapon MD; Jetsrisuparb, Charoon MD

Journal of Pediatric Hematology/Oncology: July 2010 - Volume 32 - Issue 5 - pp 400-403
doi: 10.1097/MPH.0b013e3181e015b0
Clinical and Laboratory Observations

Some iron-overloaded patients have problems being treated with iron chelators. We therefore retrospectively studied 7 iron-overloaded thalassemic patients. Within the same week, patients received 20 to 30 mg/kg/d of oral deferasirox for 4 consecutive days, then a subcutaneous infusion of 20 to 40 mg/kg/d of desferrioxamine for 8 to 12 hours on the next 3 consecutive days. The median treatment duration was 25 months (range, 8 to 32). All of the patients showed a decrease in serum ferritin without any side effects. The protocol, combining deferasirox and desferrioxamine in sequence, was effective and safe: more cases should be studied.

Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand

This study had no funding support.

Reprints: Arunee Jetsrisuparb, MD, Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand (e-mail: arujet@kku.ac.th, arujet@gmail.com).

Received for publication December 15, 2009; accepted March 8, 2010

© 2010 Lippincott Williams & Wilkins, Inc.